Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Expert Rev Cardiovasc Ther. 2010 Jun;8(6):767-70. doi: 10.1586/erc.10.62.

Contemporary management of patients with Type 2 diabetes.

Author information

  • 1University of Utah Pharmacotherapy Outcomes Research Center, 421 Wakara Way, Room 208, Salt Lake City, UT 84108, USA. carrie.mcadam-marx@pharm.utah.edu

Abstract

EVALUATION OF: Okerson T, Yan P, Stonehouse A, Brodows R. Effects of exenatide on systolic blood pressure in subjects with Type 2 diabetes. Am. J. Hypertens. 23(3), 334-339 (2010). Type 2 diabetes is often accompanied by other comorbidities that similarly contribute to cardiovascular risk. New antidiabetics including glucagon-like peptide-1 agonists have demonstrated blood glucose control in patients with Type 2 diabetes with a low risk of hypoglycemia and a favorable impact on bodyweight. Evidence suggests that these agents may convey benefit in managing additional cardiovascular risks. In a recent pooled analysis of randomized controlled trial data, Okerson et al. identified a significant reduction in systolic blood pressure in patients treated with exenatide, particularly in patients with elevated systolic blood pressure. This study provides further evidence that glucagon-like peptide-1 agonists confer therapeutic benefit for managing Type 2 diabetes while also managing other cardiovascular risk factors.

Comment on

PMID:
20528633
[PubMed]

Publication Types

Publication Types

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Informa Healthcare
    Loading ...
    Write to the Help Desk